David Toung says the FDA panel is not expected to approve the resumption of JNJ's vaccine this week. For the company, the vaccine issue may not be a material concern to the company's earnings and revenue Medical devices are expected to show robust growth due to elective procedures and consumer health products are expected to show improving sales.
20 Apr 2021
The Watch List
08 Feb 2022
Morning Trade Live
28 Mar 2022
Trading 360
23 Feb 2022
Trading 360
11 Apr 2022
Trading 360
19 Apr 2022
The Watch List
22 Mar 2022